Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study.

However, the difference in IRAEs between frail and nonfrail patients did not reach statistical significance for patients experiencing severe (grade 3–4) toxicity or treatment discontinuation constituting the most clinically relevant outcomes.

also in 111,027 other papers